A case for screening real-world data for collateral drug benefits: Glucagon-like peptide 1 receptor agonists and bile acid diarrhea.

Martin Torp Rahbek,Lars Christian Lund,Jesper Hallas

Pharmacoepidemiology and drug safety（2023）

引用 0|浏览0

暂无评分

摘要

Using the SSA methodology, we obtained estimates of a collateral drug benefit that were compatible with trial results. These results support the use of epidemiological analyses of observational data as instrument for detecting collateral drug benefits.

查看译文

关键词

bile acid associated diarrhea, collateral drug benefit, glucagon-like peptide 1 receptor agonists, sequence symmetry analysis

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要